"Policies that weaken the reliability of patent protections will only make it more difficult for U.S. startups and inventors to continue pursuing breakthroughs that benefit patients."
Learn more about why we oppose the ETHIC Act: https://t.co/KoRN0xXWYy
.@USIJorg is a group of inventors, startup companies, venture capitalists, incubators, and research institutions who have come together in the interest of safeguarding our nation's innovation ecosystem. Explore more about our mission: https://t.co/C8MDJha9gB
Although strong patents play a crucial role in promoting innovation in the drug industry and beyond, lawmakers and activists cite myths about how patent rights affect competition to justify legislation that would weaken patents.
This one-pager sets the record straight ⬇️
https://t.co/z8RGRdUlh1
The U.S. patent system is the foundation for the most innovative and dynamic economy in the world. See our suggestions on how to protect it: https://t.co/L1kz70SVvp
ICYMI: @Council4IP's Andrei Iancu and Dave Kappos recently wrote for @TheHill about what the Trump administration should take from this year's Special 301 Report. Learn more: https://t.co/xqpotkCNJq
Today, USIJ submitted a letter to the House Judiciary Committee, urging the Committee to reject the Eliminating Thickets to Increase Competition (ETHIC) Act. Learn about why the bill would actually discourage innovation in our letter: https://t.co/BcGtVDDYGm
DYK? Research from the USPTO, the FDA, and leading scholars shows that the pharmaceutical patent system is working as intended, supporting innovation while enabling competition. Learn more with this great resource from @CenterProtectIP: https://t.co/VF5cKySWLH
Earlier this year, Ambassador Jeffrey Gerrish joined Andy Hooser of @HooserReason to discuss Trump 2.0, trade, and tariffs. Check out the interview: https://t.co/QWME7BPNrb
"Importing these foreign price controls would dramatically weaken America's negotiating position. Foreign governments could refuse President Trump and Ambassador Greer's demands -- and then watch as Congress' policy automatically brings U.S. prices down to other countries' artificially low floor, rather than bringing other countries up towards America's standard. That'd crater domestic research and manufacturing investments."
In his recent op-ed for @RealClearHealth, fmr Deputy USTR Jeff Gerrish discusses why MFN is a misguided policy -- and the best way President Trump can end foreign free-riding. Read it here: https://t.co/YOR7xM8yEF
These "patent thicket" narratives don't hold water. Generics account for 90% of U.S. prescriptions, and the effective market exclusivity period for brand-name drugs has remained stable for decades. More: https://t.co/LFNY9cGuF3
Patent Thickets Block Affordable Medicines.
Brand-name drug companies use patent thickets to stack dozens of overlapping patents and delay generic competition, instead of focusing on innovating new medicines. This keeps drug prices high!
Policymakers must act NOW to rein in patent thickets and bring affordable medicines to America’s patients faster.
Learn more: https://t.co/5rjWOYKn3Y
Enforceable patents are essential to protect startups from the predatory behavior of would-be competitors who are anxious to copy any new product or technology once it is proven workable.
Learn more: https://t.co/1mSNJnh8tT
.@USIJorg's Chris Israel wrote for @InsideSourcesDC about how the U.S. patent system is stacked against small inventors.
Read his op-ed here: https://t.co/3DuRkXcD4G
Our members are committed to promoting a strong intellectual property system that supports innovation, investment, and breakthrough technologies that change our world.
Learn more about them here: https://t.co/scEGDDa9iN
DYK that calls to weaken patent rights -- based on claims of “patent thickets” or low-quality patents -- are not supported by the evidence and risk undermining the innovation ecosystem that makes new drug development possible?
Learn more: https://t.co/fnwvcRUyZz
It is difficult and perilous to start any new company from scratch. The process requires visionary people willing to give up secure jobs, take risks, and join companies that have a significant possibility of failure. Learn how patents support this process: https://t.co/1mSNJnh8tT
"A patent without the credible prospect of an injunction is not a true property right. Foreign jurisdictions that categorically deny injunctions to U.S. patent holders are expropriating American property. USTR is right to raise this issue in the strongest possible terms."
@USIJorg praises the 2026 Special 301 Report's defense of injunctive relief. See our full statement: https://t.co/nO9yYezhmG
"American startups, universities, innovators, and venture investors have waited a long time for a Special 301 Report that takes their concerns seriously. The 2026 Report does. We look forward to collaborating with USTR to ensure that it has consequences and real impact in the market."
See our full statement: https://t.co/nO9yYezhmG